Medical technology company GE HealthCare has secured 510(k) clearance from the US Food and Drug Administration for its CARESCAPE Canvas patient-monitoring platform.
The CARESCAPE Canvas and CARESCAPE ONE are components of an adaptable ecosystem that can easily adjust the monitoring capabilities according to the acuity level of each patient, enabling both scaling up and scaling down monitoring as required.
GE HealthCare monitoring solutions general manager Neal Sandy said: “GE HealthCare is committed to offering flexible solutions that enable care teams to focus on the patient, not the technology.
“CARESCAPE Canvas’ innovative approach, where software and patient parameters can change in a very nimble manner, enables a standardised ecosystem that can adapt to changing healthcare needs.”
The CARESCAPE Canvas platform is equipped with FlexAcuity software and measurement technologies to help healthcare providers personalise care as needed. It features a smart parameter technology that caters to patients at varying levels of acuity.
By using micromodules that connect with standardised medical USB technology, this monitoring platform provides ease of use and flexibility to provide successful outcomes.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The CARESCAPE Canvas bedside monitor underwent comprehensive development and testing with the current devices and prior versions of the company’s ecosystem.
The manufacturing of CARESCAPE Canvas monitors at the company’s facility in Helsinki, Finland, is carried out entirely using renewable wind electricity, ensuring that the monitors are produced sustainably.
Last month, GE HealthCare completed patient enrolment in Phase I of its early clinical development programme for a manganese-based macrocyclic magnetic resonance imaging contrast agent.